



THE PRESCRIBER e-LETTER

Change to the Management of Zepbound® (tirzepatide) for MassHealth Patients with Diabetes and Overweight or Obesity Beginning October 1, 2025

Effective October 1, 2025, MassHealth is implementing a step therapy requirement for patients with both diabetes and overweight or obesity who are newly requesting Zepbound® (tirzepatide) treatment. Members with diabetes initiating treatment with Zepbound® (tirzepatide) will be required to step through Mounjaro® (tirzepatide) first or document medical necessity for use of Zepbound® (tirzepatide).

Members with approved prior authorizations for Zepbound® (tirzepatide) will be able to continue to receive Zepbound® (tirzepatide) until their currently approved prior authorization expires. Upon resubmission to continue therapy, members with diabetes and overweight or obesity, who are stable on Zepbound® (tirzepatide), will be required to transition to Mounjaro® (tirzepatide) as part of the prior authorization renewal process or document medical necessity for use of Zepbound® (tirzepatide).

Zepbound® (tirzepatide) and Mounjaro® (tirzepatide) contain the same active medication and are identical in dosing and administration frequency. Prior authorization criteria for Zepbound® (tirzepatide) and Mounjaro® (tirzepatide) can be found on the MassHealth Drug List.

The MassHealth Drug List is on the MassHealth Pharmacy Program website at www.mass.gov/masshealth/pharmacy.

The Prescriber e-Letter is an update designed to enhance the transparency and efficiency of the MassHealth drug prior-authorization (PA) process and the MassHealth Drug List. Each issue highlights key clinical information and updates to the MassHealth Drug List. The Prescriber E-Letter was prepared by the MassHealth Drug Utilization Review Program, the MassHealth Pharmacy Program.